Entrada Therapeutics clears 10 mg/kg Cohort 2 start in ELEVATE-45-201 DMD trial for ENTR-601-45

Entrada Therapeutics Inc

TRDA

0.00

Entrada Therapeutics’ independent safety committee backed starting Cohort 2 at a higher dose in its ELEVATE-45-201 study for Duchenne muscular dystrophy.
The decision follows a review of available safety and pharmacokinetics from Cohort 1, with participants moving into the open-label Phase 2 portion.
Results have not been presented; Cohort 1 safety, early pharmacokinetics, and early dystrophin data are expected in mid-2026.
The move keeps the program on track to test higher doses across later cohorts, supporting a broader readout sequence into Cohorts 2 and 3.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606020700PRIMZONEFULLFEED9729881) on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.